MiniMed Group (NASDAQ:MMED) Price Target Raised to $28.00 at UBS Group

MiniMed Group (NASDAQ:MMED) had its price target upped by stock analysts at UBS Group from $25.00 to $28.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 17.94% from the stock’s previous close.

Several other brokerages have also issued reports on MMED. Bank of America lifted their target price on shares of MiniMed Group from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday. Benchmark reaffirmed a “buy” rating on shares of MiniMed Group in a research note on Thursday, June 4th. Wells Fargo & Company lowered their price objective on MiniMed Group from $26.00 to $22.00 and set an “overweight” rating on the stock in a research note on Thursday, June 4th. Weiss Ratings raised shares of MiniMed Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. Finally, BTIG Research upped their price objective on shares of MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday. Thirteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, MiniMed Group currently has an average rating of “Moderate Buy” and a consensus price target of $23.08.

MiniMed Group Stock Performance

Shares of MiniMed Group stock opened at $23.74 on Wednesday. MiniMed Group has a fifty-two week low of $10.65 and a fifty-two week high of $22.74. The stock has a 50-day moving average price of $17.65. The firm has a market capitalization of $6.68 billion and a P/E ratio of -34.48.

MiniMed Group (NASDAQ:MMED) last announced its earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The firm had revenue of $837.00 million during the quarter. The business’s revenue was up 15.6% on a year-over-year basis. As a group, sell-side analysts expect that MiniMed Group will post 0.66 earnings per share for the current fiscal year.

Institutional Trading of MiniMed Group

Several hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System acquired a new stake in MiniMed Group during the 2nd quarter worth approximately $89,000. Legal & General Group Plc acquired a new position in MiniMed Group during the 2nd quarter worth approximately $91,000. The Manufacturers Life Insurance Company purchased a new stake in MiniMed Group during the second quarter worth about $185,000. Punch & Associates Investment Management Inc. purchased a new stake in shares of MiniMed Group in the 2nd quarter worth about $292,000. Finally, Washington Growth Strategies LLC purchased a new stake in shares of MiniMed Group during the second quarter worth about $397,000.

MiniMed Group News Summary

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: MiniMed reported fiscal Q1 net sales of $843 million, up 17% year over year, while organic U.S. revenue growth accelerated to 13%. International sales also grew strongly, supporting management’s decision to raise its fiscal 2027 organic revenue-growth guidance. MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
• Positive Sentiment: Fiscal Q1 earnings per share of approximately $0 exceeded analyst expectations, contributing to the favorable initial market reaction. Earnings Flash: MiniMed Posts Fiscal Q1 EPS
• Positive Sentiment: MiniMed highlighted progress across its product pipeline, including an FDA submission for MiniMed Fit, a CE Mark for MiniMed Flex, completion of enrollment in the Vivera pivotal trial and IDE approval for a next-generation extended-wear sensor. MiniMed Group Q1 2027 Deep Dive
• Positive Sentiment: Analyst sentiment strengthened after the results. Mizuho raised its target from $21 to $26 with an “outperform” rating; Bank of America lifted its target from $24 to $28 with a “buy” rating; and BTIG also raised its target to $28 and maintained a “buy” rating.
• Negative Sentiment: The reported brokerage consensus target of $21.62 remains below the stock’s recent trading level, indicating that not all analysts have fully reflected the latest operating momentum in their estimates. MiniMed Receives Consensus Target Price from Brokerages

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.